Evaluation of droplet digital PCR rapid detection method and precise diagnosis and treatment for suspected sepsis (PROGRESS): a study protocol for a multi-center pragmatic randomized controlled trial

• Published in: BMC infectious diseases Vol. 22; no. 1; pp. 1 - 630
• Main Authors: Zhao, Yuanhan, Lin, Ke, Zhang, Haocheng, Yuan, Guanmin, Zhang, Yanliang, Pan, Jingye, Hong, Liang, Huang, Yan, Ye, Ying, Huang, Lisu, Chen, Xiaohua, Liu, Jun, Li, Xiang, He, Xiaoju, Yue, Qiaoyan, Zhang, Hong, Zhou, Aiming, Zhuang, Yangyang, Chen, Jie, Wu, Caixia, Zhou, Wei, Cai, Fujing, Zhang, Shengguo, Li, Liang, Li, Shaling, Bian, Tingting, Li, Jiabin, Yin, Jun, Ruan, Zhengshang, Xu, Shanshan, Zhang, Yan, Zhang, Ying, Han, Jun, Su, Tingting, Tu, Fan, Jiang, Lijing, Lei, Chen, Du, Qiu, Ai, Jingwen, Zhang, Wenhong
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 19.07.2022; BioMed Central; BMC
• Subjects: Antibiotics; Antimicrobial resistance; Assaying; Blood; Blood culture; Care and treatment; Causes of; China; Diagnosis; Droplets; Drug resistance in microorganisms; Emergency medical services; Enrollments; Etiology; Evaluation; Health services; Hospitals; Infectious diseases; Intensive care units; Medical examination; Medicine; Methods; Morbidity; Mortality; Multicenter; Pathogens; Patients; Physicians; Prevention; Public health; Randomized trial; Rapid diagnostics; Risk factors; Sepsis; Septic shock; Statistics; Study Protocol; China
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-022-07557-2

Abstract Background Sepsis is still a major public health concern and a medical emergency due to its high morbidity and mortality. Accurate and timely etiology diagnosis is crucial for sepsis management. As an emerging rapid and sensitive pathogen detection tool, digital droplet PCR (ddPCR) has shown promising potential in rapid identification of pathogens and antimicrobial resistance genes. However, the diagnostic value and clinical impact of ddPCR tests remains to be studied in patients with suspected sepsis. PROGRESS trial is aimed to evaluate the clinical effectiveness of a novel ddPCR assay compared with standard practice. Methods PROGRESS is a multicenter, open-label, pragmatic randomized controlled trial (pRCT) set in ten hospitals, including departments of infectious disease and intensive care units. In this study, a total of 2292 patients with suspected sepsis will be randomly assigned to two arms: the ddPCR group and the control group with a ratio of 3:1. The primary outcome is the diagnostic efficacy, that is, the sensitivity and specificity of the ddPCR assay compared with the synchronous blood culture. Secondary outcomes include the mortality rates and the mean Sequential Organ Failure Assessment (SOFA) score at follow-up time points, the length of stay in the hospital, the time to directed antimicrobial therapy, duration of broad-spectrum antibiotic use, and the EQ-5D-5L score on day 90. Discussion It is the first multicenter pragmatic RCT to explore the diagnostic efficacy and clinical impact of the ddPCR assay in patients with suspected sepsis, taking advantage of both RCT’s ability to establish causality and the feasibility of pragmatic approaches in real-world studies (RWS). This trial will help us to get a comprehensive view of the assay’s capacity for precise diagnosis and treatment of sepsis. It has the potential to monitor the pathogen load change and to guide the antimicrobial therapy, making a beneficial impact on the prognosis of sepsis patients. Trial registration : ClinicalTrial.gov, NCT05190861. Registered January 13, 2022—‘Retrospectively registered’, https://clinicaltrials.gov/ct2/show/NCT05190861 .